Kymera Therapeutics (KYMR)
108.49
+2.51 (2.37%)
Upcoming Events
Latest Headlines
Citi reiterates buy rating on Nektar Therapeutics with $151 target
October 5, 2026 6:57 AM - StreetInsider
Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
October 5, 2026 5:24 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $150 at Citi
October 5, 2026 5:03 AM - StreetInsider
Form 4 Kymera Therapeutics, For: Oct 01 Filed by: Mainolfi Nello
October 1, 2026 5:20 PM - SEC Filing
Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello
October 1, 2026 4:10 PM - SEC Filing
Wells Fargo names 13 stocks as overweight tactical ideas
October 1, 2026 6:30 AM - StreetInsider
B.Riley Reiterates Buy Rating on Kymera Therapeutics (KYMR)
October 1, 2026 5:06 AM - StreetInsider
Goldman Sachs Resumes Kymera Therapeutics (KYMR) at Early-Stage Biotech
September 24, 2026 5:36 AM - StreetInsider
Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'
September 23, 2026 8:41 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $152 at Stifel on Ph2b BROADEN2 Data
September 21, 2026 4:34 PM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $144 at BofA Securities
September 14, 2026 5:43 AM - StreetInsider
Wolfe Research Upgrades Kymera Therapeutics (KYMR) to Outperform
September 10, 2026 5:33 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $140 at JPMorgan
September 2, 2026 9:22 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim
August 31, 2026 7:09 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $151 at Wells Fargo
August 27, 2026 7:14 AM - StreetInsider
TD Cowen Assumes Kymera Therapeutics (KYMR) at Buy
August 22, 2026 7:54 AM - StreetInsider
Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
August 14, 2026 10:39 AM - SEC Filing
Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
August 13, 2026 4:43 PM - SEC Filing
Kymera Therapeutics (KYMR) PT Raised to $135 at Morgan Stanley
August 6, 2026 8:52 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $139 at Barclays
August 6, 2026 4:19 AM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $125 at Oppenheimer
August 5, 2026 2:56 PM - StreetInsider
Kymera Therapeutics (KYMR) PT Raised to $132 at Stifel
August 5, 2026 10:42 AM - StreetInsider
Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c
August 5, 2026 7:30 AM - StreetInsider
Form 10-Q Kymera Therapeutics, For: Jun 30
August 5, 2026 7:16 AM - SEC Filing
Form 8-K Kymera Therapeutics, For: Aug 05
August 5, 2026 7:10 AM - SEC Filing
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
August 5, 2026 7:00 AM - Globe NewsWire
Deutsche Bank Starts Kymera Therapeutics (KYMR) at Hold
July 30, 2026 2:12 AM - StreetInsider
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
July 28, 2026 4:01 PM - Globe NewsWire
Kymera Therapeutics (KYMR) PT Raised to $135 at Guggenheim
July 28, 2026 6:40 AM - StreetInsider
Form 4 Kymera Therapeutics, For: Jul 27 Filed by: Rooney Terence
July 27, 2026 6:34 PM - SEC Filing
Form 3 Kymera Therapeutics, For: Jul 27 Filed by: Rooney Terence
July 27, 2026 6:25 PM - SEC Filing
Form 8-K Kymera Therapeutics, For: Jul 27
July 27, 2026 4:10 PM - SEC Filing
Kymera Therapeutics names new chief medical officer
July 27, 2026 4:01 PM - StreetInsider
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
July 27, 2026 4:01 PM - Globe NewsWire
Kymera Therapeutics (KYMR) PT Raised to $140 at Mizuho
July 16, 2026 5:29 AM - StreetInsider
Kymera Therapeutics (KYMR) call put ratio 1 call to 3.3 puts with a focus on December 95 and 100 puts as share price down 8%
July 13, 2026 2:07 PM - StreetInsider
Full Article List
